Insulet Corporation ($PODD) Stock Forecast: Down 6.8% Today

What is Insulet Corporation?

Insulet Corp (PODD) is a medical device company recognized for its Omnipod insulin management system, specializing in automated insulin delivery systems for diabetes patients.

Why is Insulet Corporation going down?

PODD stock is down 6.8% on Jun 11, 2026 13:50

• The bearish movement in Insulet Corp (PODD) stock today is linked to various factors:
• Despite positive clinical data on the Omnipod 6 system for type 2 diabetes, the stock lagged behind its rivals and the broader market, resulting in a 5.58% decline.
• A 5.3% surge in shares may suggest robust fundamentals and undervaluation; however, the stock showed an overall negative performance for the day.
• The stock's price fluctuations and volatility could be impacted by market sentiment, investor confidence, and potential worries regarding product concentration and quality concerns.
• In summary, the mixed performance of Insulet Corp (PODD) stock today highlights the company's continuous endeavors to enhance its automated insulin delivery systems, alongside the challenges of maintaining market competitiveness and investor confidence.

PODD Price Chart

PODD Technical Analysis

PODD News

Does Insulet’s (PODD) Omnipod 6 Data Reframe Its Type 2 Diabetes Automation Ambitions?

Insulet recently presented new clinical data on its Omnipod 6 and fully closed-loop system for type 2 diabetes, showing improved glucose control and patient satisfaction. These developments, alongside updates to the Omnipod 5 platform, are crucial for Insulet's investment narrative, which relies on the expansion of its automated insulin delivery system, particularly into the type 2 diabetes market. The positive data supports an optimistic outlook for type 2 adoption, though product concentration and quality issues remain risks for investors.

https://simplywall.st/stocks/us/healthcare/nasdaq-podd/insulet/news/does-insulets-podd-omnipod-6-data-reframe-its-type-2-diabete

Insulet Corp. stock underperforms Wednesday when compared to competitors

Insulet Corp. (PODD) stock fell 5.58% to $150.71 on Wednesday, significantly underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines of 1.62% and 1.87%, respectively. Insulet Corp. closed 57.53% below its 52-week high.

https://www.marketwatch.com/data-news/insulet-corp-stock-underperforms-wednesday-when-compared-to-competitors-52f3421e-a164017e9f6f

Insulet Corp (PODD) Shares Surge 5.3% -- What GF Score of 82 Tel

Insulet Corp (PODD) shares surged 5.3% despite a challenging year, with the stock currently down significantly year-to-date and over the past year. GuruFocus' GF Value™ indicates the stock is significantly undervalued at $159.61 compared to its intrinsic value of $391.37, while its GF Score™ of 82/100 points to strong overall fundamentals, particularly in growth and profitability. Insider buying activity suggests confidence in the company's future prospects.

https://www.gurufocus.com/news/8908887/insulet-corp-podd-shares-surge-53-what-gf-score-of-82-tells-investors

Insulet Corp. stock outperforms competitors on strong trading day

Insulet Corp. (PODD) stock saw a positive performance, rising 2.22% to $183.67, significantly outperforming competitors despite a slight dip in the broader market. This gain follows a trend of outperforming both its industry and the S&P 500 year-to-date, suggesting a robust market position.

https://www.msn.com/en-us/money/topstocks/insulet-corp-stock-outperforms-competitors-on-strong-trading-day/ar-AA25dWPV?ocid=finance-verthp-feeds

Insulet Corp. stock outperforms competitors on strong trading day

Shares of Insulet Corp. (PODD) rose 5.35% to $159.61 on Tuesday, outperforming the mixed stock market where the Dow Jones Industrial Average gained slightly and the S&P 500 Index declined. The company's stock closed 55.02% below its 52-week high of $354.88.

https://www.marketwatch.com/data-news/insulet-corp-stock-outperforms-competitors-on-strong-trading-day-340eb47c-f8835ddfe29e

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 5.5% Today

Insulet Corporation Price History

10.05.2026 - PODD Stock was down 5.0%

• Insulet Corp's stock faced bearish pressure, which could be attributed to profit-taking following recent increases, despite the company's robust fundamentals and insider purchases showing faith in its performance.
• While the stock has been outperforming competitors and the market, a notable decline from its 52-week peak may have led to some selling activity.
• The purchase of company shares by Insulet's Independent Chair, Timothy Christian, might indicate enduring confidence in the company's growth prospects, potentially offsetting short-term pessimism.
• Today's downturn in Insulet Corp's stock could be influenced by profit-taking, market dynamics, and investor response to recent insider transactions, despite the company's strong market position and growth trajectory.

27.04.2026 - PODD Stock was down 6.0%

• The recall of approximately 7 million Omnipod insulin pods due to a manufacturing defect causing insulin leakage has led to a loss of investor confidence in Insulet Corporation.
• The voluntary medical device correction announcement, along with the expected costs of up to $50 million in 2026, has raised concerns about the company's financial performance and operational efficiency.
• The identified cause of the manufacturing issue, the implementation of corrective actions, and the provision of free replacements show Insulet's commitment to product quality and customer safety, but the market reaction remains negative due to the potential impact on sales and reputation.

27.04.2026 - PODD Stock was down 6.0%

• Insulet Corporation's stock plummeted to a 52-week low of $143.95, marking a challenging year with a 52.46% decline. The significant drop is linked to a voluntary recall of about 7 million Omnipod insulin pods due to a manufacturing defect. This has raised concerns among investors about product safety and future sales.
• The recall of 7 million patch pumps in the Omnipod product line due to a manufacturing defect leading to insulin leakage and potential medication under-delivery has sparked worries about the company's quality control processes and financial implications, with anticipated costs of up to $50 million this year.
• Despite maintaining a Buy rating, analysts at BTIG have slashed the price target for Insulet Corporation from $260 to $235, indicating revised near-term expectations for the Omnipod product line. This shift has contributed to investor concerns and a reassessment of the company's prospects in the competitive medical device sector.
• The negative outlook for medical device firms is further highlighted by Boston Scientific's stock decline of 6% following a reduction in its full-year guidance. This demonstrates the challenges facing the industry and the broader impact on market performance in the sector.

27.04.2026 - PODD Stock was down 7.4%

• The downturn in Insulet Corporation's stock (PODD) is linked to a recall of around 7 million Omnipod insulin pods due to a manufacturing flaw causing insulin leakage, raising concerns about product quality and impact on sales and revenue.
• Boston Scientific’s stock decline by over 6% post a reduction in full-year organic growth guidance potentially influenced negative investor sentiment in the healthcare sector, triggering a wider sell-off affecting companies like Insulet Corporation.
• Despite Insulet Corporation's efforts in rectifying the manufacturing issue through a voluntary correction, the projected costs of up to $50 million in 2026 and the subsequent impact on adjusted results likely pressured the stock price further.
• Ongoing industry uncertainties, exemplified by challenges faced by Boston Scientific and Insulet Corporation, are contributing factors to the bearish trend observed in Insulet Corporation's stock (PODD) today.

09.05.2026 - PODD Stock was up 5.2%

• Insulet Corp. (PODD) exhibited bearish movements as it underperformed its competitors, resulting in a lower closing price despite the overall market trending positively.
• This decline could be linked to investors taking profits following the recent consecutive increases in stock value, prompting a sell-off.
• To boost investor confidence and push the stock price upwards, the company may need to showcase more robust growth prospects or release positive developments in the future.

05.05.2026 - PODD Stock was up 5.4%

• Strong insider confidence, with notable purchases by the Independent Chair and CEO at higher prices, may have fueled the bullish movement in PODD stock today, signaling optimism regarding the company's future.
• The recent improvements in Insulet's Omnipod 5 Automated Insulin Delivery System post FDA clearance likely played a role in the positive market sentiment, demonstrating the company's dedication to advancing their products.
• Despite a recent voluntary medical device correction for certain Omnipod insulin pods, the overall upbeat attitude stemming from insider transactions and product upgrades appears to have overshadowed any apprehensions, driving the bullish trend in PODD stock today.

13.04.2026 - PODD Stock was down 5.1%

• The stock of Insulet rose by 3.4% after the initiation of coverage by Benchmark, demonstrating a positive outlook despite its significant yearly decrease.
• The stock's upward movement was also fueled by the announcement of its strategic expansion into the Middle East and North Africa through a new regional headquarters.
• The ongoing investor interest in Insulet’s user-friendly diabetes management solutions is evident from the positive market response, despite the stock's overall downtrend this year.
• Insulet's consistent gains while major indices were experiencing mixed trading showcase the company's resilience and potential for growth compared to the broader market.

11.05.2026 - PODD Stock was down 6.8%

• The bearish movement in Insulet Corp (PODD) stock today is linked to various factors:
• Despite positive clinical data on the Omnipod 6 system for type 2 diabetes, the stock lagged behind its rivals and the broader market, resulting in a 5.58% decline.
• A 5.3% surge in shares may suggest robust fundamentals and undervaluation; however, the stock showed an overall negative performance for the day.
• The stock's price fluctuations and volatility could be impacted by market sentiment, investor confidence, and potential worries regarding product concentration and quality concerns.
• In summary, the mixed performance of Insulet Corp (PODD) stock today highlights the company's continuous endeavors to enhance its automated insulin delivery systems, alongside the challenges of maintaining market competitiveness and investor confidence.

07.04.2026 - PODD Stock was up 6.8%

• Insulet (PODD) stock saw a 6.3% surge after surpassing expectations in their Q1 results and raising their full-year revenue outlook. This growth was primarily fueled by strong international Omnipod sales and improved profitability.
• Despite concerns over second-quarter guidance and anticipated revenue growth slowdown, Truist Securities reduced Insulet's price target to $250 from $315 but still maintains a Buy rating, anticipating positive results in the future.
• Insulet posted impressive Q1 2026 earnings, beating expectations with an EPS of $1.42, achieving a 30% revenue growth, and expanding their operating margin. Their optimistic full-year revenue guidance and focus on innovation and global expansion contributed to the positive stock movement.
• Analysts are adjusting price targets based on a balance of strong financial performance and valuation worries, with RBC Capital remaining optimistic about Insulet's exceptional financial standing while adjusting the price target to $280.

02.05.2026 - PODD Stock was down 5.1%

• The overturning of the $59.4 million trade secret verdict against rival EOFlow could have created uncertainty among investors, leading to a sell-off of Insulet's stock.
• The decline in Insulet's stock price target from $379 to $294 by TD Cowen, along with other analyst actions, might have contributed to the bearish movement as investors reevaluate their positions.
• The lack of success in CareDx's appeal for a $45 million false advertising award against Natera Inc. could have impacted market sentiment towards medical device companies like Insulet.
• Despite the overall bearish movement, it's worth noting that Insulet had outperformed the broader market in the past few trading sessions, indicating potential volatility in response to industry-specific news.

04.05.2026 - PODD Stock was up 5.8%

• The bullish movement in Insulet's stock (PODD) can be attributed to multiple positive developments within the company:
• New data and innovations for the Omnipod brand were announced at a key industry event, displaying improved clinical outcomes and streamlined diabetes management.
• A significant purchase of 3,450 shares by director Elizabeth H. Weatherman at an average price of $144.20 per share demonstrated confidence in the company's future prospects.
• Mike Panos has been appointed as Chief Commercial Officer, leveraging extensive experience in the medtech sector to propel growth for Insulet's Omnipod platform.
• Enhancements for the Omnipod 5 Automated Insulin Delivery System were launched, incorporating personalized health tech features and expanded sensor compatibility to strengthen Insulet's position in the competitive diabetes technology market. These advancements likely influenced the bullish movement in Insulet's stock.

14.04.2026 - PODD Stock was down 5.5%

• Insulet Corporation's stock hit a 52-week low and dropped 6.7% due to nine analyst downgrades and price target cuts, reflecting a fundamental reassessment of the company's near-term prospects.
• Despite strong Q1 financial results, concerns about guidance and valuation led to a significant decline in the stock price.
• The coordinated action of analyst firms, including Barclays maintaining an Underweight rating, suggests potential uncertainties regarding Insulet's competitive dynamics or guidance revisions.
• Benchmark initiating coverage and a 3.4% rise in shares amid a challenging year-to-date performance indicate ongoing interest in Insulet's user-friendly solutions for diabetes management, despite today's bearish market movement.